5-Fluorowillardiine

Last updated
5-Fluorowillardiine
5-Fluorowillardiine.svg
Names
Other names
2-Amino-3-(5-fluoro-2,4-dioxopyrimidin-1-yl)propanoic acid
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard 100.162.280 OOjs UI icon edit-ltr-progressive.svg
PubChem CID
UNII
  • InChI=1S/C7H8FN3O4/c8-3-1-11(2-4(9)6(13)14)7(15)10-5(3)12/h1,4H,2,9H2,(H,13,14)(H,10,12,15) Yes check.svgY
    Key: DBWPFHJYSTVBCZ-UHFFFAOYSA-N Yes check.svgY
  • InChI=1/C7H8FN3O4/c8-3-1-11(2-4(9)6(13)14)7(15)10-5(3)12/h1,4H,2,9H2,(H,13,14)(H,10,12,15)
    Key: DBWPFHJYSTVBCZ-UHFFFAOYAR
  • NC(CN1C=C(F)C(=O)N=C1O)C(O)=O
Properties
C7H8FN3O4
Molar mass 217.156 g·mol−1
log P -1.168
Acidity (pKa)2.118
Basicity (pKb)11.879
Isoelectric point 4.28
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

5-Fluorowillardiine is a selective agonist for the AMPA receptor, [1] [2] [3] with only limited effects at the kainate receptor. [4] It is an excitotoxic neurotoxin when used in vivo and so is rarely used in intact animals, but it is widely used to selectively stimulate AMPA receptors in vitro. [5] [6] [7] It is structurally similar to the compound willardiine, which is also an agonist for the AMPA and kainate receptors. Willardiine occurs naturally in Mariosousa willardiana and Acacia sensu lato. [8] [9]

Contents

The name is unusual as it has two successive i's. This is not a typo.

Toxicity

(S)-5-Fluorowillardiine activity has been studied in vitro in a variety of neural tissues. In mouse embryo hippocampal neurons, it was found to desensitize AMPA/kainate receptors with an EC50 of 1.5 μM –— 7 times more potent than racemic AMPA (EC50 of 11 μM). [10] In another study, (S)-5-Fluorowillardiine showed biphasic dose-dependent neurotoxicity in cultural rodent cortical neurons, with EC50 values of 0.70 and 170 μM. [11] While in vivo research is sparse, a study in 5-day-old mice injected with the closely related AMPA/kainate agonist (S)-5-Bromowillardiine showed cortical and white matter damage. AMPA antagonists reduced the extent of the damage in a dose-dependent fashion. [12]

Applications in research

Radiolabeled 5-fluorowillardiine has been used to study the distribution of ionotropic glutamate receptors in rodent brains. [13] It has also been used to evaluate the effects of various allosteric modulators of the AMPA receptor. [14]

Chemistry

Structure and activity

Synthesis of 5-fluorowillardiine 5-fluorowillardiine.jpg
Synthesis of 5-fluorowillardiine

5-fluorowillardiine is derived from the nitrogenous base uracil found in RNA. It is one member of a family of willardiine compounds, which share uracil or a substituted uracil as an amino acid side chain. 5-Fluorowillardiine exists as two distinct isomers:

The particularly high affinity of 5-fluorowillardiine for the AMPA receptor is attributed to its fluorine substituent at the 5-position of the ring, which is electron-withdrawing and small enough to not interfere with binding. By contrast, related willardiine derivatives with larger nonpolar electron withdrawing groups exhibit greater affinity for kainate receptors than 5-fluorowillardiine, and less affinity for AMPA receptors. [15]

The binding of 5-fluorowillardiine to the AMPA receptor is driven by entropy when its ring is uncharged. When the ring is deprotonated and has a negative charge, a favorable change in enthalpy primarily drives binding. Because the pKa values of halogenated willardiine derivates are approximately 8 (7.98 for 5-Fluorowillardiine), binding is mostly driven by an increase in entropy at physiological pH. [16]

Synthesis

The synthesis of 5-Fluorowillardiine may be achieved by using 5-Fluorouracil as a nucleophile to open a specialized lactone in an SN2 reaction. Another straightforward approach is to perform a Strecker amino acid synthesis. [17] [18]

Related Research Articles

<i>N</i>-Methyl-<small>D</small>-aspartic acid Amino acid derivative

N-methyl-D-aspartic acid or N-methyl-D-aspartate (NMDA) is an amino acid derivative that acts as a specific agonist at the NMDA receptor mimicking the action of glutamate, the neurotransmitter which normally acts at that receptor. Unlike glutamate, NMDA only binds to and regulates the NMDA receptor and has no effect on other glutamate receptors. NMDA receptors are particularly important when they become overactive during, for example, withdrawal from alcohol as this causes symptoms such as agitation and, sometimes, epileptiform seizures.

<span class="mw-page-title-main">AMPA receptor</span> Transmembrane protein family

The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor is an ionotropic transmembrane receptor for glutamate (iGluR) that mediates fast synaptic transmission in the central nervous system (CNS). It has been traditionally classified as a non-NMDA-type receptor, along with the kainate receptor. Its name is derived from its ability to be activated by the artificial glutamate analog AMPA. The receptor was first named the "quisqualate receptor" by Watkins and colleagues after a naturally occurring agonist quisqualate and was only later given the label "AMPA receptor" after the selective agonist developed by Tage Honore and colleagues at the Royal Danish School of Pharmacy in Copenhagen. The GRIA2-encoded AMPA receptor ligand binding core was the first glutamate receptor ion channel domain to be crystallized.

<span class="mw-page-title-main">NMDA receptor</span> Glutamate receptor and ion channel protein found in nerve cells

The N-methyl-D-aspartatereceptor (also known as the NMDA receptor or NMDAR), is a glutamate receptor and ion channel found in neurons. The NMDA receptor is one of three types of ionotropic glutamate receptors, the other two being AMPA and kainate receptors. Depending on its subunit composition, its ligands are glutamate and glycine (or D-serine). However, the binding of the ligands is typically not sufficient to open the channel as it may be blocked by Mg2+ ions which are only removed when the neuron is sufficiently depolarized. Thus, the channel acts as a “coincidence detector” and only once both of these conditions are met, the channel opens and it allows positively charged ions (cations) to flow through the cell membrane. The NMDA receptor is thought to be very important for controlling synaptic plasticity and mediating learning and memory functions.

<span class="mw-page-title-main">CNQX</span> Chemical compound

CNQX or cyanquixaline (6-cyano-7-nitroquinoxaline-2,3-dione) is a competitive AMPA/kainate receptor antagonist. Its chemical formula is C9H4N4O4. CNQX is often used in the retina to block the responses of OFF-bipolar cells for electrophysiology recordings.

<span class="mw-page-title-main">UBP-302</span> Chemical compound

UBP-302 is a highly selective kainate receptor antagonist used in the study of many neurological processes. It is active at micromolar concentration within an in vitro preparation and specifically targets the GluK1 (iGluR5) subunit of the receptor. This compound was developed at the University of Bristol.

<span class="mw-page-title-main">Kainate receptor</span> Class of ionotropic glutamate receptors

Kainate receptors, or kainic acid receptors (KARs), are ionotropic receptors that respond to the neurotransmitter glutamate. They were first identified as a distinct receptor type through their selective activation by the agonist kainate, a drug first isolated from the algae Digenea simplex. They have been traditionally classified as a non-NMDA-type receptor, along with the AMPA receptor. KARs are less understood than AMPA and NMDA receptors, the other ionotropic glutamate receptors. Postsynaptic kainate receptors are involved in excitatory neurotransmission. Presynaptic kainate receptors have been implicated in inhibitory neurotransmission by modulating release of the inhibitory neurotransmitter GABA through a presynaptic mechanism.

<span class="mw-page-title-main">Metabotropic glutamate receptor</span> Type of glutamate receptor

The metabotropic glutamate receptors, or mGluRs, are a type of glutamate receptor that are active through an indirect metabotropic process. They are members of the group C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatory neurotransmitter.

<span class="mw-page-title-main">Evans blue (dye)</span> Chemical compound

T-1824 or Evans blue, often incorrectly rendered as Evan's blue, is an azo dye that has a very high affinity for serum albumin. Because of this, it can be useful in physiology in estimating the proportion of body water contained in blood plasma. It fluoresces with excitation peaks at 470 and 540 nm and an emission peak at 680 nm.

<span class="mw-page-title-main">Quisqualic acid</span> Chemical compound

Quisqualic acid is an agonist of the AMPA, kainate, and group I metabotropic glutamate receptors. It is one of the most potent AMPA receptor agonists known. It causes excitotoxicity and is used in neuroscience to selectively destroy neurons in the brain or spinal cord. Quisqualic acid occurs naturally in the seeds of Quisqualis species.

Muscarinic acetylcholine receptor M<sub>1</sub> Protein-coding gene in the species Homo sapiens

The muscarinic acetylcholine receptor M1, also known as the cholinergic receptor, muscarinic 1, is a muscarinic receptor that in humans is encoded by the CHRM1 gene. It is localized to 11q13.

<span class="mw-page-title-main">Metabotropic glutamate receptor 4</span> Mammalian protein found in humans

Metabotropic glutamate receptor 4 is a protein that in humans is encoded by the GRM4 gene.

<span class="mw-page-title-main">Alpha-7 nicotinic receptor</span>

The alpha-7 nicotinic receptor, also known as the α7 receptor, is a type of nicotinic acetylcholine receptor implicated in long-term memory, consisting entirely of α7 subunits. As with other nicotinic acetylcholine receptors, functional α7 receptors are pentameric [i.e., (α7)5 stoichiometry].

<span class="mw-page-title-main">IDRA-21</span> Chemical compound

IDRA-21 is a positive allosteric modulator of the AMPA receptor and a benzothiadiazine derivative. It is a chiral molecule, with (+)-IDRA-21 being the active form.

<span class="mw-page-title-main">Cyclothiazide</span> Chemical compound

Cyclothiazide, sometimes abbreviated CTZ, is a benzothiadiazide (thiazide) diuretic and antihypertensive that was originally introduced in the United States in 1963 by Eli Lilly and was subsequently also marketed in Europe and Japan. Related drugs include diazoxide, hydrochlorothiazide, and chlorothiazide.

<span class="mw-page-title-main">5-Iodowillardiine</span> Chemical compound

5-Iodowillardiine is a selective agonist for the kainate receptor, with only limited effects at the AMPA receptor. It is selective for kainate receptors composed of GluR5 subunits. It is an excitotoxic neurotoxin in vivo, but has proved highly useful for characterising the subtypes and function of the various kainate receptors in the brain and spinal cord.

In pharmacology and biochemistry, allosteric modulators are a group of substances that bind to a receptor to change that receptor's response to stimuli. Some of them, like benzodiazepines or alcoholic beverages, function as psychoactive drugs. The site that an allosteric modulator binds to is not the same one to which an endogenous agonist of the receptor would bind. Modulators and agonists can both be called receptor ligands.

<span class="mw-page-title-main">S-18986</span> Chemical compound

S-18986 is a positive allosteric modulator of the AMPA receptor related to cyclothiazide. It has nootropic and neuroprotective effects in animal studies, and induces both production of BDNF and AMPA-mediated release of noradrenaline and acetylcholine in the hippocampus and frontal cortex of the brain.

<span class="mw-page-title-main">25CN-NBOH</span> Chemical compound

25CN-NBOH is a compound indirectly derived from the phenethylamine series of hallucinogens, which was discovered in 2014 at the University of Copenhagen. This compound is notable as one of the most selective agonist ligands for the 5-HT2A receptor yet discovered, with a pKi of 8.88 at the human 5-HT2A receptor and with 100x selectivity for 5-HT2A over 5-HT2C, and 46x selectivity for 5-HT2A over 5-HT2B. A tritiated version of 25CN-NBOH has also been accessed and used for more detailed investigations of the binding to 5-HT2 receptors and autoradiography.

<span class="mw-page-title-main">Willardiine</span> Chemical compound

Willardiine (correctly spelled with two successive i's) or (S)-1-(2-amino-2-carboxyethyl)pyrimidine-2,4-dione is a chemical compound that occurs naturally in the seeds of Mariosousa willardiana and Acacia sensu lato. The seedlings of these plants contain enzymes capable of complex chemical substitutions that result in the formation of free amino acids (See: #Synthesis). Willardiine is frequently studied for its function in higher level plants. Additionally, many derivates of willardiine are researched for their potential in pharmaceutical development. Willardiine was first discovered in 1959 by R. Gmelin, when he isolated several free, non-protein amino acids from Acacia willardiana (another name for Mariosousa willardiana) when he was studying how these families of plants synthesize uracilyalanines. A related compound, Isowillardiine, was concurrently isolated by a different group, and it was discovered that the two compounds had different structural and functional properties. Subsequent research on willardiine has focused on the functional significance of different substitutions at the nitrogen group and the development of analogs of willardiine with different pharmacokinetic properties. In general, Willardiine is the one of the first compounds studied in which slight changes to molecular structure result in compounds with significantly different pharmacokinetic properties.

<span class="mw-page-title-main">TAK-653</span> Experimental antidepressant

TAK-653 is an experimental drug being investigated as a treatment for treatment-resistant depression. It is being developed by Takeda.

References

  1. Patneau, DK; Mayer, ML; Jane, DE; Watkins, JC (1992). "Activation and Desensitization of AMPA / Kainate Receptors by Novel Derivatives of Willardiine". Journal of Neuroscience. 12 (2): 595–606. doi:10.1523/JNEUROSCI.12-02-00595.1992. PMC   6575614 . PMID   1371315.
  2. Hawkins, LM; Beaver, KM; Jane, DE; Taylor, PM; Sunter, DC; Roberts, PJ (1995). "Characterization of the pharmacology and regional distribution of (S)-3H-5-fluorowillardiine binding in rat brain". British Journal of Pharmacology . 116 (3): 2033–9. doi:10.1111/j.1476-5381.1995.tb16408.x. PMC   1908955 . PMID   8640342.
  3. Lunn, ML; Ganakas, AM; Mercer, LD; Lawrence, AJ; Beart, PM (1996). "Localisation and properties of AMPA-insensitive kainate sites: receptor autoradiography and gene expression in rat brain". Neuroscience Letters. 204 (1–2): 121–4. doi:10.1016/0304-3940(96)12335-1. PMID   8929993. S2CID   36885666.
  4. Larm, JA; Cheung, NS; Beart, PM (1996). "(S)-5-fluorowillardiine-mediated neurotoxicity in cultured murine cortical neurones occurs via AMPA and kainate receptors". European Journal of Pharmacology. 314 (1–2): 249–54. doi:10.1016/S0014-2999(96)00633-4. PMID   8957243.
  5. Jensen, RJ (1999). "Responses of directionally selective retinal ganglion cells to activation of AMPA glutamate receptors". Visual Neuroscience. 16 (2): 205–19. doi:10.1017/s0952523899162023. PMID   10367956. S2CID   42955027.
  6. Olivera, S; Rodriguez-Ithurralde, D; Henley, JM (2001). "Regional localization and developmental profile of acetylcholinesterase-evoked increases in 3H-5-fluorowillardiine binding to AMPA receptors in rat brain". British Journal of Pharmacology. 133 (7): 1055–62. doi:10.1038/sj.bjp.0704167. PMC   1572873 . PMID   11487516.
  7. Kessler, M; Arai, AC (2006). "Use of 3H fluorowillardiine to study properties of AMPA receptor allosteric modulators". Brain Research. 1076 (1): 25–41. doi:10.1016/j.brainres.2005.09.024. PMID   16256076. S2CID   28267484.
  8. Klaassen, C. D.; John Barr Watkins (2010). "Toxic Agents" (PDF). Casarett and Doull's essentials of toxicology. USA: McGraw-Hill Prof Med/Tech. p. 374. ISBN   978-0-07-176651-7.
  9. Atta-ur- Rahman (2000). "Interference of Alkaloids" (PDF). Bioactive Natural Products (Part B), Part 2. Amsterdam: Alsevier Science B. V. p. 72. ISBN   9780080542010.
  10. Patneau, DK; Mayer, ML; Jane, DE; Watkins, JC (1 February 1992). "Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine". The Journal of Neuroscience. 12 (2): 595–606. doi: 10.1523/JNEUROSCI.12-02-00595.1992 . PMC   6575614 . PMID   1371315.
  11. Larm, Jari A.; Cheung, Nam Sang; Beart, Philip M. (October 1996). "(S)-5-Fluorowillardiine-mediated neurotoxicity in cultured murine cortical neurones occurs via AMPA and kainate receptors". European Journal of Pharmacology. 314 (1–2): 249–254. doi:10.1016/S0014-2999(96)00633-4. PMID   8957243.
  12. Gressens, Pierre; Spedding, Michael; Gigler, Gabor; Kertesz, Szabolcs; Villa, Pascal; Medja, Fadia; Williamson, Toni; Kapus, Gabor; Levay, Gyorgy; Szenasi, Gabor; Barkoczy, Jozsef; Harsing, Laszlo G. (September 2005). "The effects of AMPA receptor antagonists in models of stroke and neurodegeneration". European Journal of Pharmacology. 519 (1–2): 58–67. doi:10.1016/j.ejphar.2005.06.031. PMID   16112106.
  13. Hawkins, L.M.; Beaver, K.M.; Jane, D.E.; Taylor, P.M.; Sunter, D.C.; Roberts, P.J. (October 1995). "Characterization of the pharmacology and regional distribution of (S)-[3H]-5-fluorowillardiine binding in rat brain". British Journal of Pharmacology. 116 (3): 2033–2039. doi:10.1111/j.1476-5381.1995.tb16408.x. PMC   1908955 . PMID   8640342.
  14. Kessler, Markus; Arai, Amy C. (March 2006). "Use of [3H]fluorowillardiine to study properties of AMPA receptor allosteric modulators". Brain Research. 1076 (1): 25–41. doi:10.1016/j.brainres.2005.09.024. PMID   16256076. S2CID   28267484.
  15. Jane, David E.; Hoo, Ken; Kamboj, Raj; Deverill, Michele; Bleakman, David; Mandelzys, Allan (October 1997). "Synthesis of Willardiine and 6-Azawillardiine Analogs: Pharmacological Characterization on Cloned Homomeric Human AMPA and Kainate Receptor Subtypes". Journal of Medicinal Chemistry. 40 (22): 3645–3650. doi:10.1021/jm9702387. PMID   9357531.
  16. Martinez, Madeline; Ahmed, Ahmed H.; Loh, Adrienne P.; Oswald, Robert E. (5 June 2014). "Thermodynamics and Mechanism of the Interaction of Willardiine Partial Agonists with a Glutamate Receptor: Implications for Drug Development". Biochemistry. 53 (23): 3790–3795. doi: 10.1021/bi500511m . PMC   4215890 . PMID   24850223.
  17. Jane, David E.; Hoo, Ken; Kamboj, Raj; Deverill, Michele; Bleakman, David; Mandelzys, Allan (October 1997). "Synthesis of Willardiine and 6-Azawillardiine Analogs: Pharmacological Characterization on Cloned Homomeric Human AMPA and Kainate Receptor Subtypes". Journal of Medicinal Chemistry. 40 (22): 3645–3650. doi:10.1021/jm9702387. PMID   9357531.
  18. Dewar, J. H.; Shaw, G. (1962). "110. Purines, pyrimidines, and imidazoles. Part XVII. A synthesis of willardiine". Journal of the Chemical Society (Resumed): 583. doi:10.1039/JR9620000583.